Lung Cancer Non-Small Cell Cancer (NSCLC) Active Not Recruiting Phase 2 Trials for Carboplatin (DB00958)

Also known as: Non - Small Cell Lung Cancer NSCLC / Carcinoma, Non-Small-Cell Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma / Nonsmall Cell Lung Cancer / Lung Cancer(NSCLC) / Non-Small Cell Lung Cancer / Non-Small-Cell Lung Cancer (NSCLC) / NSCLC (Non-Small Cell Lung Cancer) / Non Small Cell Lung Cancer (NSCLC) / Lung Cancer (Non-Small Cell) / NSCLC, Non Small Cell Lung Cancer / Non-small Cell Lung Cancers / Lung Cancer, Nonsmall Cell / Non-Small Cell Lung Carcinoma / Lung Cancer Non-Small Cell / Non-Small-Cell Lung Cancer / Non-Small Cell Lung Cancer (NSCLC) / Non Small Cell Lung Cancer / Non-Small Cell Lung Carcinoma (NSCLC) / Carcinoma, Non-Small Cell Lung / Lung Cancer, Non-Small Cell / Non Small-cell Lung Cancer / NSCLC Non-small Cell Lung Cancer / NSCLC / Non Small Cells Lung Cancer / Non-Small Cell Lung Cancer(NSCLC) / Non- Small Cell Lung Cancer / Lung Cancer - Non Small Cell / Lung Cancer (NSCLC) / Non Small Cell Lung Cancer NSCLC / Non-Small-Cell-Lung Cancer (NSCLC) / Non-Small-Cell-Lung Cancer / Non-small cell lung cancer (disorder) / Non-small cell lung cancer NOS

IndicationStatusPhase
DBCOND0046916 (Lung Cancer Non-Small Cell Cancer (NSCLC))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01980472Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer PatientsOther
NCT03664024Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)Treatment
NCT03081689Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsTreatment
NCT02591615Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLCTreatment
NCT02659059Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerTreatment
NCT02525757MPDL3280A With Chemoradiation for Lung CancerTreatment
NCT02186847Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung CancerTreatment
NCT02716038Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLCTreatment
NCT02710396Genetic Predictors of Benefit to PembrolizumabTreatment